Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
IPO Year:
Exchange: NASDAQ
Website: novavax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2024 | $8.00 | Neutral → Underweight | JP Morgan |
| 5/10/2024 | $4.00 → $12.00 | Underperform → Neutral | BofA Securities |
| 5/10/2024 | Underweight → Neutral | JP Morgan | |
| 8/9/2023 | $15.00 | Neutral → Buy | B. Riley Securities |
| 4/20/2023 | $55.00 → $10.00 | Outperform → Market Perform | TD Cowen |
| 3/1/2023 | $29.00 → $10.00 | Buy → Neutral | B. Riley Securities |
| 1/9/2023 | $74.00 → $37.00 | Buy | B. Riley Securities |
| 12/30/2022 | $207.00 → $110.00 | Buy | H.C. Wainwright |
| 12/2/2022 | Hold | Jefferies | |
| 9/22/2022 | $132.00 → $27.00 | Neutral → Underweight | JP Morgan |
S-8 - NOVAVAX INC (0001000694) (Filer)
8-K - NOVAVAX INC (0001000694) (Filer)
10-Q - NOVAVAX INC (0001000694) (Filer)
8-K - NOVAVAX INC (0001000694) (Filer)
8-K - NOVAVAX INC (0001000694) (Filer)
DEFA14A - NOVAVAX INC (0001000694) (Filer)
8-K - NOVAVAX INC (0001000694) (Filer)
8-K - NOVAVAX INC (0001000694) (Filer)
8-K - NOVAVAX INC (0001000694) (Filer)
10-Q - NOVAVAX INC (0001000694) (Filer)
Doses of Novavax's 2024-2025 Formula COVID-19 vaccine now available at thousands of locations nationwideNovavax's updated vaccine is the only protein-based option available in the U.S. this fall for individuals aged 12 and olderGAITHERSBURG, Md., Sept. 13, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the U.S.
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences. H.C. Wainwright 26th Annual Global Investment Conference: Fireside Chat Date: Monday, September 9, 2024 Time: 3:30 – 4:00 p.m. Eastern Time (ET) Location: New York City, New York Moderator: Vernon Bernardino, Managing Director, Senior Healthcare Analyst Novavax participants: Jim Kelly, Executive Vice President, Chief Financial Officer and Treasurer and Robert Walker, MD, Senior Vice President, Chief Medical Officer and Interim Head, Research and Developm
Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S.Novavax's vaccine is the only protein-based option available in the U.S. for use in individuals aged 12 and older to prevent COVID-19GAITHERSBURG, Md., Aug. 30, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older. Novavax's vaccine is included in the recom
Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in CashFiled with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccineReceived $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnershipPhase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025Company to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Aug. 8, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announc
GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows: Conference call details: Date: August 8, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3XTduSS Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering the
Novavax's COVID-19 vaccine would be the only protein-based option available in Canada, if authorizedNovavax's filing is aligned with NACI, U.S. FDA, EMA and WHO recommendations on vaccine compositionGAITHERSBURG, Md., July 2, 2024 /CNW/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for authorization with Health Canada for its 2024-2025 Formula COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission follows the National Advisory Committee on Immunization (NACI) guidance to use the latest selected strain and the guidance from the U.S. Food and Drug Administration (FDA), Europea
Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3GAITHERSBURG, Md., June 24, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from EMA and the World Health Organization to target the JN.1 lineage this fall.1,2 "Novavax is working closely with European markets seeking to offer a protein-based alternative to mRNA
Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U.S. Novavax's filing is aligned with FDA, EMA and WHO global recommendations on vaccine compositionNovavax intends to have its vaccine in pre-filled syringes available in the U.S. for immediate release post-authorization and following recommendation by the U.S. CDCGAITHERSBURG, Md., June 14, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an amendment to its Emergency Use Authori
GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 6, 2024 Time: 12:30 – 12:55 p.m. Eastern Time (ET) Location: New York, NY Moderator: Roger Song, MD, CFA, Equity Research Analyst – Biotechnology Novavax participant: John C. Jacobs, President and Chief Executive Officer Conference Event: Investor Meetings Date: Thursday, June 6, 2024 RecordingsA replay of the recorded fireside session will be available through the Events & Presentations page of t
Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value Still Remains to Be Unlocked at Novavax Still Believes Novavax Would Benefit from Stockholder Representative on Board RALEIGH, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Shah Capital Management, Inc. (together with its affiliates, "Shah Capital," "we" or "our") collectively beneficially owns ~7.9% of the outstanding common stock of Novavax, Inc. (NASDAQ:NVAX) ("Novavax" or the "Company"), making it a top three and largest non-index stockholder, today issued the below statement to stockholders regarding its intended efforts at the 2024 Annual Meeting of Stockholders scheduled for Thursday,
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
SC 13D/A - NOVAVAX INC (0001000694) (Subject)
SC 13D/A - NOVAVAX INC (0001000694) (Subject)
SC 13D/A - NOVAVAX INC (0001000694) (Subject)
SC 13D - NOVAVAX INC (0001000694) (Subject)
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
SC 13G - NOVAVAX INC (0001000694) (Subject)
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
SC 13G - NOVAVAX INC (0001000694) (Subject)
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management's failure to capitalize on Novavax's many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outdated and old-fashioned marketing RALEIGH, N.C., April 15, 2024 (GLOBE NEWSWIRE) -- Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax (NASDAQ:NVAX), ha
New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plansJohn Trizzino appointed to new Chief Operating Officer roleMark Casey to join as Chief Legal Officer and Corporate SecretaryGAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week. John Trizzino will take on the newly created role of President and Ch
Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline developmentGAITHERSBURG, Md., Jan. 9, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John C. Jacobs will succeed Stanley C. Erck as President and Chief Executive Officer and a member of the Board of Directors. The transition will be effective as of January 23, 2023.
GAITHERSBURG, Md., Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Richard Rodgers, MBA to its board as an independent director. Mr. Rodgers brings extensive experience in biopharmaceutical management to his role on the Novavax Board of Directors. "Rick's deep experience in the pharmaceutical industry coupled with his extensive acumen in building rapidly growing companies and financial leadership will be invaluable as we continue the commercialization of our COVID-19 vaccine and expand our vaccine pipeline," said Stanley C.
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serves as the Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, which he co-founded and built, with end-to-end manufacturing and digital s
GAITHERSBURG, Md., Aug. 16, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, and Nasir Egal, Ph.D. as Senior Vice President, Quality Assurance. Mr. Kelly will report to Stanley C. Erck, President and Chief Executive Officer, and Dr. Egal will report to Rick Crowley, Executive Vice President and Chief Operations Officer. Mr. Kelly brings more than twenty-five years of industry experience in both commercial and clinical-stage companies to Novavax. He joins Novavax from Supernus Pharma
GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief Scientist, and the appointment of Troy Morgan as Senior Vice President, Chief Compliance Officer. The company also announced that Greg Covino will be stepping down as Chief Financial Officer (CFO) and will take on a new role as executive adviser to the company. Recognized as a pioneer in vaccine research, Dr. Smith is the senior inventor of the insect cell technology that serves as the basis of N
GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief Scientist, and the appointment of Troy Morgan as Senior Vice President, Chief Compliance Officer. The company also announced that Greg Covino will be stepping down as Chief Financial Officer (CFO) and will take on a new role as executive adviser to the company. Recognized as a pion
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn ‘Lyn’ Caltabiano, Ph.D. to the position of Senior Vice President, Global Program Management. In this newly created role, Dr. Caltabiano will lead and expand the Global Program Management organization for the company’s pipeline and will develop appropriate strategies to assess the company’s operational performance, including areas related to portfolio valuation, milestone decision making and prioritization. She will report directly to Stanley C. Erck, President and
GAITHERSBURG, Md., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Henrietta Ukwu, M.D., FACP, FRAPS, to the position of Senior Vice President, Chief Regulatory and Quality Officer. In this newly created role, Dr. Ukwu will lead global regulatory strategy and execution as well as the quality assurance function for the company’s development-stage vaccine candidates, including its recombinant protein-based COVID-19 candidate vaccine, NVX-CoV2373. “Dr. Ukwu brings extensive regulatory affairs and quality expertise and leadership experience
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons
For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of
For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO
For Immediate Release: September 13, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA reissued the Aug. 19, 2022, letter of authorization for Novavax COVID-19 Vaccine, Adjuvanted to revise the conditions of authorization related to the Vaccine Adverse Event Reporting System (VAERS) reporting requirements for vaccination pr
For Immediate Release: July 13, 2022 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. “Authorizing an additional COVID-19 vaccine expands the available vaccine options for the preventi
Novavax's (NYSE:NVAX) short percent of float has fallen 25.64% since its last report. The company recently reported that it has 29.53 million shares sold short, which is 25.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.78 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
More than half of the states in the U.S. are experiencing significant Covid-19 activity in wastewater, and President Joe Biden remains in isolation after announcing Wednesday he caught the virus for the third time. Twenty-six states are reporting either “high” or “very high” levels of the virus at various sites, according to the latest data from the Centers for Disease Control and Prevention. States with the highest levels include Arkansas, California, Florida, Maryland, Nevada, Oregon and Texas. The Biden administration no longer considers Covid-19 a public health emergency and instead treats it as a routine respiratory virus to be prevented through an annual vaccination campaign,
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 15.42% on an annualized basis producing an average annual return of 28.56%. Currently, Novavax has a market capitalization of $2.34 billion. Buying $100 In NVAX: If an investor had bought $100 of NVAX stock 5 years ago, it would be worth $345.87 today based on a price of $15.91 for NVAX at the time of writing. Novavax's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed b
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 15.36% on an annualized basis producing an average annual return of 29.01%. Currently, Novavax has a market capitalization of $2.42 billion. Buying $100 In NVAX: If an investor had bought $100 of NVAX stock 5 years ago, it would be worth $356.62 today based on a price of $16.40 for NVAX at the time of writing. Novavax's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed b
U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday. Shares of UnitedHealth Group Incorporated (NYSE:UNH) rose sharply during Tuesday's session following a second-quarter earnings beat. The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from Benzinga Pro. UnitedHealth’s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare. UnitedHealth Group shares gained 5.7% to $544.96 on Tuesday. Here are some other big stocks recording gains in today’s
Novavax, Inc. (NASDAQ:NVAX) shares are moving higher on Monday. Here’s what you need to know. What To Know: The company announced on July 2 that it has filed for authorization with Health Canada for its updated 2024-2025 protein-based COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. If approved, this would be the only protein-based COVID-19 vaccine option available in Canada. Novavax's updated vaccine targets the JN.1 variant and has shown broad neutralization responses against multiple variant strains, which could make it a significant option for public health programs. What Else: Novavax has also submitted filings with the U.S. FDA and EMA and is working with other r
Novavax's (NYSE:NVAX) short percent of float has risen 3.9% since its last report. The company recently reported that it has 39.71 million shares sold short, which is 34.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.82 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is im
Whales with a lot of money to spend have taken a noticeably bullish stance on Novavax. Looking at options history for Novavax (NASDAQ:NVAX) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 80% of the investors opened trades with bullish expectations and 20% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $238,432 and 7, calls, for a total amount of $255,012. Predicted Price Range Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.5 to $17.5 for Novavax over the last 3 months. Insights into Volume & Open Interest In today's trading
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 6.35% on an annualized basis producing an average annual return of 19.29%. Currently, Novavax has a market capitalization of $2.03 billion. Buying $1000 In NVAX: If an investor had bought $1000 of NVAX stock 5 years ago, it would be worth $2,341.30 today based on a price of $13.75 for NVAX at the time of writing. Novavax's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewe
Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in CashFiled with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccineReceived $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnershipPhase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025Company to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Aug. 8, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announc
GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows: Conference call details: Date: August 8, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3XTduSS Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering the
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:$500 million upfront payment Approximately $70 million equity investment in NovavaxUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to P
GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024. Details of the event and replay are as follows: Conference call details: Date: May 10, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3VNP8J5 Dial-in number: (888) 664-6383 (Domestic) or (+1) (416) 764-8650 (International) Webcast: ir.novavax.com/events Participants can join t
Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billionAccelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza Combination vaccine trial in second half 2024 and potential 2026 launchRescaled global footprint with 30% total headcount reduction as compared to Q1 2023Announced settlement with Gavi related to 2021 advance purchase agreement, removing financial uncertainty and enabling focus on shared public health mission Provided full year 2024 total revenue guidance of $800 million to $1 billionCompany to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Feb. 28, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advanci
GAITHERSBURG, Md., Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Wednesday, February 28, 2024. Details of the event and replay are as follows: Conference call details: Date: February 28, 2024 Time: 8:30 a.m. U.S. EST URL to register phone: https://emportal.ink/3SqJSJv Dial-in number: (888) 664-6383 (Domestic) or (+1) (617) 892-4906 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistanc
GAITHERSBURG, Md., Aug. 1, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its second quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Daylight Time (EDT) on Tuesday, August 8, 2023. Details of the event and replay are as follows: Conference call details: Date: August 8, 2023 Time: 8:30 a.m. U.S. EDT Dial-in number: (877) 883-0383 (Domestic) or (412) 902-6506 (International) Passcode: 1209328 Webcast:
Announced global restructuring and cost reduction initiative with expected 2024 full-year R&D and SG&A reduction of approximately 40% to 50% vs 2022Provided full year 2023 total revenue guidance of between $1.4 and $1.6 billionFirst quarter revenue reflects shift to seasonal demand pattern; on-track to deliver updated COVID vaccine for Fall seasonAnnounced positive Phase 2 topline results for COVID-Influenza Combination, standalone influenza, and high-dose COVID vaccine candidatesCompany to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., May 9, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, t
GAITHERSBURG, Md., May 2, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m. EDT on Tuesday, May 9, 2023. Details of the event and replay are as follows: Conference call details: Date: May 9, 2023 Time: 8:30 a.m. U.S. Eastern Daylight Time (EDT) Dial-in number: (877) 883-0383 (Domestic) or (412) 902-6506 (International) Passcode: 3370620 Webcast: ir.novavax.com/events Participants will be prompted to request to join the Novavax, Inc. call.To ensure a timely connection, it is recommended that partic
Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billionAppointed John C. Jacobs as President and Chief Executive OfficerUpdated U.S. government agreement to include up to 1.5 million additional doses of Novavax's COVID-19 vaccine for delivery in 2023Expanded Nuvaxovid™ label in adult booster and adolescent primary seriesInitiated Phase 2 trial of COVID-19-Influenza Combination and stand-alone influenza vaccine candidatesCompany to host conference call today at 4:30 p.m. ETGAITHERSBURG, Md., Feb. 28, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced its fina
JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00
BofA Securities upgraded Novavax from Underperform to Neutral and set a new price target of $12.00 from $4.00 previously
JP Morgan upgraded Novavax from Underweight to Neutral
B. Riley Securities upgraded Novavax from Neutral to Buy and set a new price target of $15.00
TD Cowen downgraded Novavax from Outperform to Market Perform and set a new price target of $10.00 from $55.00 previously
B. Riley Securities downgraded Novavax from Buy to Neutral and set a new price target of $10.00 from $29.00 previously
B. Riley Securities reiterated coverage of Novavax with a rating of Buy and set a new price target of $37.00 from $74.00 previously
H.C. Wainwright reiterated coverage of Novavax with a rating of Buy and set a new price target of $110.00 from $207.00 previously
Jefferies initiated coverage of Novavax with a rating of Hold
JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $27.00 from $132.00 previously